Equity
€71,330 ▲ 11.6%
TEMAPHARM paid out €75,000 in dividends. That is 88% of the 2025 profit.
TEMAPHARM
Lifetime
7 annual accounts with figures on one time axispeak €125,634 (2025)
€125,634▲ 20.4%
peak €84,991 (2025)
€84,991▲ 14.9%
peak €79,048 (2021)
€71,330▲ 11.6%
€120,218▲ 65.2%
Board2 names since 2019
2 directorsBEAUJEAN Laurence Geneviève Dominique Marie and 1 other
Documentsfilings and deeds
25-06-202636 days before the deadline
2025micro format
Gross margin from €104,339 to €125,634Dividend €75,000Debts from €72,768 to €120,218Investments €45,604
Key points
from the 2025 annual accountsTurnover
≈ €380,000 estimated
The micro format states no turnover.
Investments
€45,604 3.1 × depreciation
Green is investment, beige is depreciation.
Filings
7 annual accounts 2 late
The 2020 accounts came latest: 31 days after the end of the period.
Starting capital
€6,200 100 shares
Position in the sector
€84,991
Higher net result than 94% of companies in retail trade. Sector median €5,052 · 22,922 companies.
Checked score
83
Excellent
Financially stronger than 64% of micro companies in retail trade (NACE 47)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.5% Low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.6% across 40,277 companies (NACE 47, micro).
About 5 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.8%
01-2025: 0.7%▼ -0.1 percentage points vs 12-2024
02-2025: 0.7%● unchanged vs 01-2025
03-2025: 0.7%● unchanged vs 02-2025
04-2025: 0.8%▲ +0.1 percentage points vs 03-2025highest value
05-2025: 0.8%● unchanged vs 04-2025
06-2025: 0.8%● unchanged vs 05-2025
07-2025: 0.4%▼ -0.4 percentage points vs 06-2025
08-2025: 0.4%● unchanged vs 07-2025
09-2025: 0.4%● unchanged vs 08-2025
10-2025: 0.4%● unchanged vs 09-2025
11-2025: 0.4%● unchanged vs 10-2025
12-2025: 0.4%● unchanged vs 11-2025
01-2026: 0.4%● unchanged vs 12-2025lowest value
02-2026: 0.4%● unchanged vs 01-2026lowest value
03-2026: 0.4%● unchanged vs 02-2026lowest value
04-2026: 0.4%● unchanged vs 03-2026
05-2026: 0.4%● unchanged vs 04-2026
06-2026: 0.4%● unchanged vs 05-2026
07-2026: 0.5%▲ +0.1 percentage points vs 06-2026
08-2026: 0.5%● unchanged vs 07-2026
09-2026: 0.5%● unchanged vs 08-2026
10-2026: 0.5%● unchanged vs 09-2026
11-2026: 0.5%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
Founded in 2019
Sector: Retail trade (NACE 47)
Size: total assets €191,548
lowers risk
Liquidity: current ratio 0.65, cash €32,479
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 53% of them on solvency, 46% on liquidity, 96% on profitability and 63% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 26,972 companies had the same profile as TEMAPHARM has now. Each dot stands for 68 companies, two years later.
94.9%
were still trading
3.4%
stopped another way
1.6%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of TEMAPHARM itself: 0.5% within 12 months.
Test of the method
The method was tested on the 497,448 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 26,972 companies, not a prediction for TEMAPHARM. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €5,000 on 30-day terms is acceptable
Liquidity is insufficient, with a current ratio of 0.65 (0.5 in 2024), below 1. Short-term debt is 48.7% and cash 17% of total assets. 62.8% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 25-06-2026, 36 days ahead of the deadline.
NBB · 7 filingsDeviation from the deadline
2025
36 days early
2024
41 days early
2023
37 days early
2022
38 days early
2021
18 days late
2020
31 days late
2019
24 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 18 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 25 June (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
11-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- WERY Benoît Joseph Ghislain 50 sharesdeed of 28-05-2019
- BEAUJEAN Laurence Geneviève Dominique Marie 50 sharesdeed of 28-05-2019
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0727468425
Incorporation
Founding capital of €6,200, 100 shares · Founders: WERY Benoît Joseph Ghislain and BEAUJEAN Laurence Geneviève Dominique Marie · Appointments: WERY Benoît Joseph Ghislain (director) and BEAUJEAN Laurence Geneviève Dominique Marie (director) · published on 28-05-2019 · Gazette deed
First establishment
Avenue des Alouettes 11, Neupré
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| TEMAPHARM Neupré | €191,548 | €125,634 | 37.2% | - |
| PHIDELTA PHARMA Liège | €216,336 | €119,730 | 24.9% | - |
| PHARMACIE CORONMEUSE Herstal | €159,928 | €149,236 | -76.5% | - |
| APOTHEEK SYNAPS PARK Genk | €189,539 | €144,275 | 89.8% | 1 |
| Pharmacie Keereman Schaerbeek | €235,291 | €114,947 | 36.9% | - |
| PHARMACIE VR Quiévrain | €223,631 | €103,045 | 29.1% | - |
| KLINICARE SHOP BENELUX Uccle | €201,725 | €90,058 | -240.6% | - |
These companies have the same main activity as TEMAPHARM: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €160,000 and €235,000, founded between 2017 and 2019.
Official details
Source: KBO- Status
- Active since 24-05-2019Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730and 2 others
- Establishment unit
- 2.290.079.9284121 Neupré, since 24-05-2019
- Financial year end
- 31 December
- Peppol
- Reachable since 02-12-2025
Annual accounts 2025
- €191,548▲ 40.1%
- Filing
- Filed on 25-06-2026, 36 days before the end of the filing period
Insights on TEMAPHARM
TEMAPHARM files the micro format. That format states no turnover. The gross margin rose from €25,192 in 2019 to €125,634 in 2025.
The balance sheet grew most in 2020 through fixed assets.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about TEMAPHARM
- What is the company number of TEMAPHARM?
- The company number of TEMAPHARM is 0727.468.425. The VAT number is the same number with BE in front: BE 0727.468.425.
- Where is TEMAPHARM based?
- The registered office is at Avenue des Alouettes 11, 4121 Neupré.Company details
- What does TEMAPHARM do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of TEMAPHARM?
- TEMAPHARM is a private limited company (BV).
- When was TEMAPHARM founded?
- TEMAPHARM was founded on 24-05-2019.
- Is TEMAPHARM still active?
- Yes, TEMAPHARM is an active enterprise in the KBO register.
- What is the turnover of TEMAPHARM?
- The turnover in financial year 2025 is ≈ €380,000. This figure is estimated from the gross margin of €125,634 and 31 comparable companies (NACE 477). It probably lies between €270,000 and €710,000. In financial year 2021 turnover was €102,093.Financials
- Is TEMAPHARM profitable?
- In financial year 2025, TEMAPHARM made a profit of €84,991.
- Where can I find the annual accounts of TEMAPHARM?
- TEMAPHARM filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of TEMAPHARM due?
- TEMAPHARM must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.